

**FOR IMMEDIATE RELEASE**

Ernest J. Schenk, Manager, Investor Relations and Communication  
(269) 673-9212  
E-mail: [Investor@perrigo.com](mailto:Investor@perrigo.com)

**PERRIGO COMPANY ANNOUNCES APPROVAL  
FOR PRESCRIPTION STRENGTH IBUPROFEN TABLETS**

ALLEGAN, Mich. – July 19, 2005 – The Perrigo Company (Nasdaq: PRGO; TASE) today announced that it has received approval from the U.S. Food and Drug Administration (FDA) to manufacture and market prescription Ibuprofen Tablets, USP 400 mg, 600 mg and 800 mg.

The product is equivalent to McNeil Consumer & Specialty Pharmaceuticals' Motrin® tablets, 400 mg, 600 mg and 800 mg, indicated for the relief of the symptoms of arthritis, and relief of mild to moderate pain.

Perrigo Company is a leading global healthcare supplier and the world's largest manufacturer of over-the-counter (OTC) pharmaceutical and nutritional products for the store brand and contract manufacturing markets. Store brand products are sold by food, drug, mass merchandise, dollar store and club store retailers under their own labels. The Company also develops, manufactures and markets prescription generic drugs, active pharmaceutical ingredients and consumer products, and operates manufacturing and logistics facilities in the United States, Israel, United Kingdom, Mexico, and Germany. Visit Perrigo on the Internet (<http://www.perrigo.com>).